Cidara Therapeutics Inc.
Cidara Therapeutics Expands Phase 3 Trial for CD388 Based on FDA Feedback
Summary
On September 24, 2025, Cidara Therapeutics, Inc. announced significant updates to its planned Phase 3 registrational trial of CD388, following feedback from the U.S. FDA. The study population will be expanded to include adults over 65 years of age with no specific co-morbidities in addition to subjects over 12 years of age with high-risk comorbidities or immune compromised status. This expansion will increase the initial number of patients potentially eligible to receive CD388 from approximately 50 million to well over 100 million people in the United States. The trial will also be accelerated, with enrollment starting by the end of September 2025 in the Northern Hemisphere and continuing into the spring of 2026 in the Southern Hemisphere. The Company intends to enroll a total of 6,000 subjects in the global, multicenter, randomized, double-blind, placebo-controlled study.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement